Introduction

Are you interested in short DAPT? Learn more…

 

featured_ultimaster_kol_interview_1_icon_masterdapt_560×344.png

What

 

The MASTER DAPT trial is and how it applies to short DAPT.

featured_ultimaster_kol_interview_1_icon_why_560×344.png

Why

 

The MASTER DAPT trial is different to other clinical studies on short DAPT?

featured_ultimaster_kol_interview_1_icon_how__560×344.png

How

 

A short DAPT protocol fits with established guidelines?

Find Answers

Dr. JS Hiremath is here to help you find some answers

 

Message from Dr.Jagdish S. Hiremath

 

 

 

study design of MASTER DAPT

 

 

master dapt protocol



 

Expert's interview about the MASTER DAPT Trial

 

Through this video, you can... 
・Address key concerns surrounding HBR DAPT management 
・Draw clarity and confidence from clinical evidence on short DAPT 
・Gain practical advice on DAPT practice change from expert

 

Watch and get insight from Dr. JS Hiremath

Summary for optimal DAPT protocol


A summary of the interview can be simple to confirm. 

You can download it in full here.

 

Read more about the MASTER DAPT Trial

 

featured_ultimaster_kol_interview_1_icon_latest_results_560×344.png

Get the trial result

Sub-analysis: Complex PCI

Read the latest results from the MASTER DAPT Complex PCI sub-analysis.

featured_ultimaster_kol_interview_1_icon_subanalysis_560×344.png

Get the trial result

Sub-analysis: OAC

Read the summary report for the MASTER DAPT OAC sub-analysis result. 

featured_ultimaster_kol_interview_1_icon_summary_560×344.png

Get the trial result

Summary of main trial 

Read the summary report of the MASTER DAPT main trial result.  

 

Product Characteristics

Our Ultimaster™ stent, used in the MASTER DAPT trial, has three innovative features which help support a short DAPT strategy.

 

1. Stent Flexibility

Flexible 80μm Cocr platform with optimal conformability to reduce mechanical stress on the vessel wall.

featured_ultimaster_kol_interview_1_characteristics_1_800×544_1.png

2. Gradient Coating Technology

Elastic gradient PDLLA-PCL short term polymer exposure mirrors biological response, promoting rapid vascular repair within 3-4 months.

featured_ultimaster_kol_interview_1_characteristics_2_800×544.png

3. Abluminal Coating Technology & Drug

Silorimus: Most proven drug on stents. Drug release matches biological response targeted abluminal drug delivery. Low Nominal drug dose: 3.9μg/mm or 0.7μg/mm2

featured_ultimaster_kol_interview_1_characteristics_3_800×544.png

 

Ultimaster NagomiTM

The Ultimaster Nagomi™ is the latest generation of the Ultimaster™ DES family, bringing excellent deliverability, larger size line-up and an even greateroverexpansion capability.

 

Learn more about Ultimaster NagomiTM

Ultimaster Nagomi™ (image)
Terumo India Skill Lab

Comprehensive range of clinical solution training to improve the patient experience

Terumo India offers a series of Live interactive and recorded webinars from therapy leaders and expert operators. Experience advances in procedural training, precision tools optimising your patient’s outcome and educational resources from the expert faculty with Terumo India Skill Lab through interactive & informative online .

 

Learn more from Skill Lab

 

Terumo India Skill Lab (Image)
Disclaimer
MASTER DAPT trial is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management group (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).